ELEVATE, a Registry of Patients With AHP

Recruiting-Observational
Written By United Porphyrias

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.

ELEVATE is a safety registry. This type of research is used to monitor the effectiveness and safety of treatments in the real world over the long term.

Eligibility

Location: Worldwide

Diagnosis: Confirmed diagnosis of an acute hepatic porphyria, including:

  • Acute Intermittent Porphyria (AIP)

  • Hereditary Coproporphyria (HCP)

  • Variegate Porphyria (VP)

Age: Must be 12+

Exclusions: Cannot be enrolled in any clinical trials for an investigational agent.

United Porphyrias
Next

EPP/XLP Parents Questionnaire